Cellular CD4 T cell responses to the diphtheria-derived carrier protein of conjugated pneumococcal vaccine and antibody response to pneumococcal vaccination in HIV-infected adults.

Abstract

BACKGROUND:

The French National Agency for AIDS and Viral Hepatitis Research (ANRS) 114 Pneumovac trial showed that a strategy combining a 7-valent pneumococcal conjugate vaccine (PCV) prime at week 0 followed by a 23-valent pneumococcal polysaccharide vaccine (PPV) boost at week 4 enhances the frequency and magnitude of immunoglobulin (Ig) G responses against Streptococcus pneumoniae polysaccharides (SPPs) compared with PPV alone. CD4 T cell responses specific to the diphtheria-derived carrier protein CRM(197) were evaluated.

METHODS:

Lymphocyte proliferative responses (LPRs) and T(H)1 cytokine T cell responses against the diphtheria-derived carrier protein CRM(197) contained in the PCV were investigated at weeks 0, 4, and 24.

RESULTS:

In the prime-boost PCV and PPV group, the magnitude of LPRs to diphtheria toxoid and CRM(197) increased at week 4 (P < .001) and persisted until week 24 (P = .08 and .13, respectively, compared with week 4). Interferon-gamma and interleukin-2 production to CRM(197) increased significantly at week 4 (P = .02 and P < .001, respectively) and remained stable until week 24 (P = .28 and P = .08, respectively). No changes were detected in the PPV group. A strong association among the magnitude of LPRs to CRM(197) at week 4, the breadth of SPP specific IgG responses at week 8 (P = .03), and sustained IgG responses at week 24 was observed. A high frequency of helper follicular CD4(+)CXCR5(+) T cells at baseline was associated with a better LPR response to CRM(197.)

CONCLUSIONS:

The PCV prime-elicited memory T cell responses were associated with better and sustained humoral SPP specific IgG responses. ClinicalTrials.gov identifier. NCT00148824.

• Authors: Claire Rabian, Inga Tschöpe, Philippe Lesprit, Christine Katlama, Jean-Michel Molina, Jean-Luc Meynard, Jean-François Delfraissy, Geneviève Chêne, Yves Lévy, ANRS 114 Pneumovac Study Group
• Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (Clin Infect Dis) Vol. 50 Issue 8 Pg. 1174-83 (Apr 15 2010) ISSN: 1537-6591 [Electronic] United States
• PMID: 20210645 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• 23-valent pneumococcal capsular polysaccharide vaccine
• Antibodies, Bacterial
• Bacterial Proteins
• Carrier Proteins
• Heptavalent Pneumococcal Conjugate Vaccine
• Immunoglobulin G
• Pneumococcal Vaccines
• CRM197 (non-toxic variant of diphtheria toxin)

Topics

• Adult
• Antibodies, Bacterial (blood)
• Bacterial Proteins (immunology)
• CD4-Positive T-Lymphocytes (immunology)
• Carrier Proteins (immunology)
• Cell Proliferation
• Female
• HIV Infections (immunology)
• Heptavalent Pneumococcal Conjugate Vaccine
• Humans
• Immunoglobulin G (blood)
• Immunologic Memory
• Male
• Middle Aged
• Pneumococcal Vaccines (immunology)
• Th1 Cells (immunology)
• Vaccination (methods)